Institution
SOCAR
About: SOCAR is a based out in . It is known for research contribution in the topics: Heart failure & Myocardial infarction. The organization has 298 authors who have published 311 publications receiving 7126 citations. The organization is also known as: SOCAR.
Topics: Heart failure, Myocardial infarction, Enhanced oil recovery, Randomized controlled trial, Placebo
Papers published on a yearly basis
Papers
More filters
••
Autonomous University of Barcelona1, National and Kapodistrian University of Athens2, Lund University3, University of Bergen4, Hannover Medical School5, University of Zurich6, Russian National Research Medical University7, SOCAR8, University of London9, Imperial College London10, Wrocław Medical University11
TL;DR: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable.
Abstract: BACKGROUND Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 μg per liter or between 100 and 299 μg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780.)
1,616 citations
••
Saint Louis University1, University of Barcelona2, University of Alberta3, University of Erlangen-Nuremberg4, Boston University5, Uppsala University Hospital6, University of East Anglia7, University of California, San Francisco8, Duke University9, Western General Hospital10, National Institutes of Health11, Tufts University12, Kagoshima University13, University of California, Los Angeles14, SOCAR15, University of Cagliari16, Sapienza University of Rome17, Tufts Medical Center18, Tampa General Hospital19, University of Toulouse20, Charité21, Stony Brook University Hospital22
TL;DR: It is concluded that "Sarcopenia, ie, reduced muscle mass, with limited mobility" should be considered an important clinical entity and that most older persons should be screened for this condition.
845 citations
••
TL;DR: In this paper, a study was designed to determine whether physician-led remote telemedical management (RTM) compared with usual care would result in reduced mortality in ambulatory patients with chronic heart failure.
Abstract: Background—This study was designed to determine whether physician-led remote telemedical management (RTM) compared with usual care would result in reduced mortality in ambulatory patients with chronic heart failure (HF). Methods and Results—We enrolled 710 stable chronic HF patients in New York Heart Association functional class II or III with a left ventricular ejection fraction ≤35% and a history of HF decompensation within the previous 2 years or with a left ventricular ejection fraction ≤25%. Patients were randomly assigned (1:1) to RTM or usual care. Remote telemedical management used portable devices for ECG, blood pressure, and body weight measurements connected to a personal digital assistant that sent automated encrypted transmission via cell phones to the telemedical centers. The primary end point was death from any cause. The first secondary end point was a composite of cardiovascular death and hospitalization for HF. Baseline characteristics were similar between the RTM (n=354) and control (n=...
586 citations
••
Imperial College London1, Erasmus University Rotterdam2, SOCAR3, Bayer Corporation4, Paris Descartes University5, University of Freiburg6, University of Edinburgh7, University of London8, Tel Aviv University9, University Health Network10, Montreal Heart Institute11, Alfred Hospital12, Sahlgrenska University Hospital13, Medisch Spectrum Twente14, Hebron University15
TL;DR: Addition of nifedipine GITS to conventional treatment of angina pectoris has no effect on major cardiovascular event-free survival and is safe and reduces the need for coronary angiography and interventions.
488 citations
••
TL;DR: An experimental study of nanofluids intended for enhanced oil recovery is presented in this paper, where an aqueous solution of anionic surface-active agents with addition of light non-ferrous metal nanoparticles was used as the focus of the study.
394 citations
Authors
Showing all 298 results
Name | H-index | Papers | Citations |
---|---|---|---|
Patrick W. Serruys | 186 | 2427 | 173210 |
Paul G. Hugenholtz | 47 | 200 | 9099 |
Jacobus Lubsen | 41 | 135 | 9274 |
Zoltán Vokó | 26 | 119 | 2371 |
P. G. Hugenholtz | 24 | 70 | 3199 |
Bridget-Anne Kirwan | 19 | 31 | 1825 |
Georg Frater | 16 | 58 | 1213 |
Sophie de Brouwer | 11 | 20 | 438 |
Torstein Kvamme | 11 | 20 | 778 |
Bridget Anne Kirwan | 10 | 16 | 3133 |
György Fráter | 9 | 13 | 563 |
Gilbert Wagener | 8 | 14 | 917 |
Philipp Ermert | 8 | 21 | 354 |
Baghir A. Suleimanov | 8 | 40 | 464 |
Farman I. Mamedov | 7 | 27 | 211 |